Drug Search Results
More Filters [+]

Tafoxiparin sodium

Alternative Names: tafoxiparin sodium, TAFOXIPARIN, DF-01, DF01
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dilafor AB
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tafoxiparin sodium

Countries in Clinic: Finland, Sweden

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Pre-Eclampsia|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PPL20

P2

Active, not recruiting

Pre-Eclampsia

2023-03-30

PPL17

P2

Completed

Pregnancy Outcomes

2023-02-14

24%

2019-000620-17

P2

Active, not recruiting

Unknown

2022-05-08

Recent News Events